131 related articles for article (PubMed ID: 32144432)
1. Aurora B kinase as a therapeutic target in acute lymphoblastic leukemia.
Goto H; Yoshino Y; Ito M; Nagai J; Kumamoto T; Inukai T; Sakurai Y; Miyagawa N; Keino D; Yokosuka T; Iwasaki F; Hamanoue S; Shiomi M; Goto S
Cancer Chemother Pharmacol; 2020 Apr; 85(4):773-783. PubMed ID: 32144432
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
Grundy M; Seedhouse C; Russell NH; Pallis M
BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
[TBL] [Abstract][Full Text] [Related]
3. Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells.
Yamauchi T; Uzui K; Shigemi H; Negoro E; Yoshida A; Ueda T
Cancer Sci; 2013 Jul; 104(7):926-33. PubMed ID: 23557198
[TBL] [Abstract][Full Text] [Related]
4. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target.
Hartsink-Segers SA; Zwaan CM; Exalto C; Luijendijk MW; Calvert VS; Petricoin EF; Evans WE; Reinhardt D; de Haas V; Hedtjärn M; Hansen BR; Koch T; Caron HN; Pieters R; Den Boer ML
Leukemia; 2013 Mar; 27(3):560-8. PubMed ID: 22940834
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia.
Dennis M; Davies M; Oliver S; D'Souza R; Pike L; Stockman P
Cancer Chemother Pharmacol; 2012 Sep; 70(3):461-9. PubMed ID: 22864876
[TBL] [Abstract][Full Text] [Related]
6. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.
Grundy M; Seedhouse C; Shang S; Richardson J; Russell N; Pallis M
Mol Cancer Ther; 2010 Mar; 9(3):661-72. PubMed ID: 20159992
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of Aurora A and B kinases effectively induces cell cycle arrest in t(8;21) acute myeloid leukemia.
Qi J; Gao X; Zhong X; Zhang N; Wang R; Zhang H; Pan T; Liu X; Yao Y; Wu Q; Niu M; Xu K
Biomed Pharmacother; 2019 Sep; 117():109113. PubMed ID: 31207577
[TBL] [Abstract][Full Text] [Related]
8. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.
Yang J; Ikezoe T; Nishioka C; Tasaka T; Taniguchi A; Kuwayama Y; Komatsu N; Bandobashi K; Togitani K; Koeffler HP; Taguchi H; Yokoyama A
Blood; 2007 Sep; 110(6):2034-40. PubMed ID: 17495131
[TBL] [Abstract][Full Text] [Related]
9. CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors.
Chen YP; Lin HJ; Chen JS; Tsai MY; Hsieh HP; Chang JY; Chen NF; Chang KC; Huang WT; Su WC; Yang ST; Chang WC; Hung LY; Chen TY
Int J Cancer; 2014 Aug; 135(3):751-62. PubMed ID: 24382688
[TBL] [Abstract][Full Text] [Related]
10. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
Helfrich BA; Kim J; Gao D; Chan DC; Zhang Z; Tan AC; Bunn PA
Mol Cancer Ther; 2016 Oct; 15(10):2314-2322. PubMed ID: 27496133
[TBL] [Abstract][Full Text] [Related]
11. Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia.
Kelvin JM; Chimenti ML; Zhang DY; Williams EK; Moore SG; Humber GM; Baxter TA; Birnbaum LA; Qui M; Zecca H; Thapa A; Jain J; Jui NT; Wang X; Fu H; Du Y; Kemp ML; Lam WA; Graham DK; DeRyckere D; Dreaden EC
J Control Release; 2023 Sep; 361():470-482. PubMed ID: 37543290
[TBL] [Abstract][Full Text] [Related]
12. Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy.
Porcelli L; Guida G; Quatrale AE; Cocco T; Sidella L; Maida I; Iacobazzi RM; Ferretta A; Stolfa DA; Strippoli S; Guida S; Tommasi S; Guida M; Azzariti A
J Transl Med; 2015 Jan; 13():26. PubMed ID: 25623468
[TBL] [Abstract][Full Text] [Related]
13. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
14. Reactive oxygen species generation and increase in mitochondrial copy number: new insight into the potential mechanism of cytotoxicity induced by aurora kinase inhibitor, AZD1152-HQPA.
Zekri A; Mesbahi Y; Ghanizadeh-Vesali S; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Anticancer Drugs; 2017 Sep; 28(8):841-851. PubMed ID: 28639950
[TBL] [Abstract][Full Text] [Related]
15. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts.
Walsby E; Walsh V; Pepper C; Burnett A; Mills K
Haematologica; 2008 May; 93(5):662-9. PubMed ID: 18367484
[TBL] [Abstract][Full Text] [Related]
16. Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.
Kelly KR; Friedberg JW; Park SI; McDonagh K; Hayslip J; Persky D; Ruan J; Puvvada S; Rosen P; Iyer SP; Stefanovic A; Bernstein SH; Weitman S; Karnad A; Monohan G; VanderWalde A; Mena R; Schmelz M; Spier C; Groshen S; Venkatakrishnan K; Zhou X; Sheldon-Waniga E; Leonard EJ; Mahadevan D
Clin Cancer Res; 2018 Dec; 24(24):6150-6159. PubMed ID: 30082475
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells.
Noronha S; Alt LAC; Scimeca TE; Zarou O; Obrzut J; Zanotti B; Hayward EA; Pillai A; Mathur S; Rojas J; Salamah R; Chandar N; Fay MJ
In Vitro Cell Dev Biol Anim; 2018 Jan; 54(1):71-84. PubMed ID: 29197031
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Aurora-B kinase activity confers antitumor efficacy in preclinical mouse models of early and advanced gastrointestinal neoplasia.
Alferez DG; Goodlad RA; Odedra R; Sini P; Crafter C; Ryan AJ; Wedge SR; Wright NA; Anderson E; Wilkinson RW
Int J Oncol; 2012 Oct; 41(4):1475-85. PubMed ID: 22858681
[TBL] [Abstract][Full Text] [Related]
19. Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.
Floc'h N; Ashton S; Taylor P; Trueman D; Harris E; Odedra R; Maratea K; Derbyshire N; Caddy J; Jacobs VN; Hattersley M; Wen S; Curtis NJ; Pilling JE; Pease EJ; Barry ST
Mol Cancer Ther; 2017 Jun; 16(6):1031-1040. PubMed ID: 28292940
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.
Schwartz GK; Carvajal RD; Midgley R; Rodig SJ; Stockman PK; Ataman O; Wilson D; Das S; Shapiro GI
Invest New Drugs; 2013 Apr; 31(2):370-80. PubMed ID: 22661287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
